This project is a collaboration between Massachusetts General Hospital-Harvard Medical School and the International Centre for Diarrheal Disease Research in Bangladesh (ICDDR,B), focused on defining protective immunity to V. cholerae infection and developing an improved cholera vaccine. The central hypothesis of this project is that V. cholerae expresses specific proteins during early infection, which generate immune responses that are protective on subsequent exposure; an ancillary hypothesis is that these proteins are not adequately expressed during colonization with available vaccine strains, and that these differences may explain the lessened efficacy of current vaccines. There are five specific aims in this project.
In Specific Aim 1, the investigators will determine the genes and proteins expressed during human infection with V. cholerae in Bangladesh, utilizing gene expression profiling by microarray in samples of stool and vomit, as well as proteomic analysis of these samples.
In Specific Aim 2, the investigators will identify proteins that are immunogenic following human infection with V. cholerae, as well as following vaccination with cholera vaccine strain Peru-15, in order to determine whether differences in gene expression between wild-type V. cholerae and Peru-15 may be correlated with differences in specific immune responses.
In Specific Aim 3, the investigators will assess the duration of immunity to key cholera antigens following both cholera and Peru-15 vaccination over a 1-year followup period. The duration of immunity will be evaluated in serum, feces, and duodenal biopsies, as well as with a newly described methodology for measuring circulating, antigen-specific memory B cells.
In Specific Aim 4, the investigators will examine which of the immune responses to in vivo-expressed proteins are protective following exposure to V. cholerae in household contacts utilizing: baseline antibody liters to key antigens in serum and feces; the increase in baseline to day 3 immunologic responses (as a marker of an anamnestic response), and the number of circulating, antigen-specific memory B cells at baseline.
In Specific Aim 5, the investigators will evaluate selected host factors for correlation with development of immune responses following cholera or Peru-15 vaccination, as well as with susceptibility to symptomatic cholera following exposure in household contacts. The long term goals of this project are to develop the theoretical underpinnings for an improved vaccine for prevention of cholera, and to accomplish substantial technology transfer and capacity building at the ICDDR,B. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI058935-08
Application #
7231415
Study Section
Special Emphasis Panel (ZAI1-GSM-M (M1))
Program Officer
Van de Verg, Lillian L
Project Start
2000-09-05
Project End
2010-04-30
Budget Start
2007-05-01
Budget End
2008-04-30
Support Year
8
Fiscal Year
2007
Total Cost
$520,532
Indirect Cost
Name
Massachusetts General Hospital
Department
Type
DUNS #
073130411
City
Boston
State
MA
Country
United States
Zip Code
02199
Bhuiyan, Taufiqur Rahman; Hoq, Mohammad Rubel; Nishat, Naoshin Sharmin et al. (2018) Assessing antigen specific HLA-DR+ antibody secreting cell (DR+ASC) responses in whole blood in enteric infections using an ELISPOT technique. Microbes Infect 20:122-129
Domman, Daryl; Chowdhury, Fahima; Khan, Ashraful I et al. (2018) Defining endemic cholera at three levels of spatiotemporal resolution within Bangladesh. Nat Genet 50:951-955
Levade, Inès; Terrat, Yves; Leducq, Jean-Baptiste et al. (2017) Vibrio cholerae genomic diversity within and between patients. Microb Genom 3:
Kauffman, Robert C; Bhuiyan, Taufiqur R; Nakajima, Rie et al. (2016) Single-Cell Analysis of the Plasmablast Response to Vibrio cholerae Demonstrates Expansion of Cross-Reactive Memory B Cells. MBio 7:
Bhuiyan, Taufiqur Rahman; Hoq, Mohammad Rubel; Nishat, Naoshin Sharmin et al. (2016) Enumeration of Gut-Homing ?7-Positive, Pathogen-Specific Antibody-Secreting Cells in Whole Blood from Enterotoxigenic Escherichia coli- and Vibrio cholerae-Infected Patients, Determined Using an Enzyme-Linked Immunosorbent Spot Assay Technique. Clin Vaccine Immunol 23:27-36
Uddin, Muhammad Ikhtear; Islam, Shahidul; Nishat, Naoshin S et al. (2016) Biomarkers of Environmental Enteropathy are Positively Associated with Immune Responses to an Oral Cholera Vaccine in Bangladeshi Children. PLoS Negl Trop Dis 10:e0005039
Hatzios, Stavroula K; Abel, Sören; Martell, Julianne et al. (2016) Chemoproteomic profiling of host and pathogen enzymes active in cholera. Nat Chem Biol 12:268-274
Aktar, Amena; Rahman, M Arifur; Afrin, Sadia et al. (2016) O-Specific Polysaccharide-Specific Memory B Cell Responses in Young Children, Older Children, and Adults Infected with Vibrio cholerae O1 Ogawa in Bangladesh. Clin Vaccine Immunol 23:427-435
Ivers, Louise C; Charles, Richelle C; Hilaire, Isabelle J et al. (2015) Immunogenicity of the Bivalent Oral Cholera Vaccine Shanchol in Haitian Adults With HIV Infection. J Infect Dis 212:779-83
Sayeed, Md Abu; Bufano, Meagan Kelly; Xu, Peng et al. (2015) A Cholera Conjugate Vaccine Containing O-specific Polysaccharide (OSP) of V. cholerae O1 Inaba and Recombinant Fragment of Tetanus Toxin Heavy Chain (OSP:rTTHc) Induces Serum, Memory and Lamina Proprial Responses against OSP and Is Protective in Mice. PLoS Negl Trop Dis 9:e0003881

Showing the most recent 10 out of 109 publications